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ABSTRACT  111 
The redox state of the neural progenitors regulates physiological processes such as neuronal 112 
differentiation, dendritic and axonal growth. The relevance of ER-associated oxidoreductases in 113 
these processes is largely unexplored. We describe a severe neurological disorder caused by biallelic 114 
loss of function variants in Thioredoxin (TRX)-Related Transmembrane-2 (TMX2), detected by exome 115 
sequencing in fourteen affected individuals from ten unrelated families presenting with congenital 116 
microcephaly, cortical polymicrogyria and other migration disorders. TMX2 encodes one of the five 117 
TMX proteins of the Protein Disulfide Isomerase family, hitherto not linked to human developmental 118 
brain disease. Our mechanistic studies on protein function show that TMX2 localizes to the ER 119 
Mitochondria-Associated-Membranes (MAMs), is involved in posttranslational modification and 120 
protein folding, and undergoes physical interaction with the MAM associated and ER folding 121 
chaperone calnexin and ER calcium pump SERCA2. These interactions are functionally relevant 122 
because TMX2-deficient fibroblasts show decreased mitochondrial respiratory reserve capacity and 123 
compensatory increased glycolytic activity. Intriguingly, under basal conditions TMX2 occurs in both 124 
reduced and oxidized monomeric form, while it forms a stable dimer under treatment with hydrogen 125 
peroxide, recently recognized as signaling molecule in neural morphogenesis and axonal pathfinding. 126 
Exogenous expression of the pathogenic TMX2 variants or of variants with in vitro mutagenized TRX 127 
domain induces a constitutive TMX2 polymerization, mimicking increased oxidative state. Altogether 128 
these data uncover TMX2 as a sensor in the MAM-regulated redox signaling pathway and identify it 129 
as a key adaptive regulator of neuronal proliferation, migration and organization in the developing 130 
brain.   131 
  132 
 133 
  134 
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INTRODUCTION 135 
The endoplasmic reticulum (ER) is responsible for the folding of one third of the human proteome. 136 
Protein folding is coordinated by ER chaperones, together with ER oxidoreductases of the Protein 137 
Disulfide Isomerase (PDI) family1. This family consists of 23 oxidoreductase proteins2 and is part of 138 
the thioredoxin (TRX) superfamily3. PDIs are characterized by the presence of at least one TRX-like 139 
domain (potentially catalytically active with sequence including two cysteines, C-X-X-C) and an ER 140 
retention domain (typically Lys-Asp-Glu-Leu/ KDEL)3; 4. In the oxidizing environment of the ER, PDIs 141 
with active site cysteines can oxidize thiol groups of newly synthesized polypeptides mediating 142 
protein folding2; 5, but can also catalyze reduction and isomerization of disulfides in misfolded 143 
proteins,  facilitating ER-associated degradation (ERAD) during the unfolded protein response (UPR)6.  144 
PDI mediated protein folding is ATP dependent and relies on precise regulation of calcium influx to 145 
the mitochondria, necessary for mitochondrial oxidative phosphorylation1 7. Since the ER is the 146 
major storage site for calcium, specialized ion channels are located at the mitochondria-associated 147 
membranes (MAMs) of the ER to assure proper calcium transport to and from the ER, e.g. 148 
sarcoplasmic-endoplasmic reticulum Ca2+-ATPase ATP2A2/SERCA2, inositol 1,4,5 trisphosphate 149 
receptor type 1 (IP3R1) and voltage-dependent anion-selective channel 1 (VDAC1)1. Besides 150 
regulating protein folding, some PDI oxidoreductases additionally function in calcium trafficking 151 
through interaction with these ER calcium channels1; 8; 9. Accordingly, some PDIs show enriched ER 152 
localization at the MAM10. Through upregulation of calcium transport into the mitochondria, PDIs 153 
are also able to regulate ATP production, necessary to increase folding mechanisms when misfolded 154 
proteins aggregate (ER-stress)1; 7; 11. Hence, PDIs and protein folding are important determinants for 155 
normal mitochondrial bioenergetics and cell survival.  156 
In humans, altered expression of PDIs has been correlated with neurodegenerative disorders like 157 
Alzheimer, Parkinson disease and amyotrophic lateral sclerosis12. However, notwithstanding their 158 
proven biological relevance, little is known about the consequence of inherited pathogenic variants 159 
in PDIs. At the moment of writing, only one heterozygous recurrent variant in P4HB (OMIM 176790 ) 160 
(Prolyl 4-hǇdƌoǆǇlase, β-subunit) encoding PDIA1has been associated with Cole-Carpenter syndrome 161 
1 (OMIM 112240), characterized by skeletal malformations (OMIM 176790)12-15. Pathogenic variants 162 
in non-PDI oxidoreductases from other protein families, e.g. WWOX (OMIM 605131)16, DHCR24 163 
(OMIM 606418) 17, NDUFS1 (OMIM 157655) 18 ,  and variants in MAM-associated genes, e.g. SERAC1 164 
(OMIM 614725) 19, MFN2 (OMIM 608507) 20, have been linked to neurodevelopmental and 165 
mitochondrial disorders.   166 
Thioredoxin (TRX)-Related Transmembrane proteins (TMX) are five type 1 transmembrane proteins 167 
belonging to the PDI family2; 3; 21. The best studied of the group, TMX1 (PDIA11) is localized at the 168 
MAM and regulates calcium trafficking through interaction with the ER calcium pump SERCA21 7. No 169 
pathogenic variants have been reported in TMX members in relation to human disease until now, 170 
although two missense variants of unknown significance in TMX3 were proposed to lead to 171 
microphthalmia22. TMX2 (PDIA12), one of the least studied of the group, is encoded by TMX2 on 172 
chromosome 11q12.1 (OMIM 616715), is ubiquitously expressed and presents in two isoforms, the 173 
longest with 296 amino acids being the most biologically relevant as ER resident protein21. The N-174 
terminal signal sequence (amino acid1-48) is followed by the cytosolic domain (amino acid49-102), 175 
the single transmembrane domain (amino acid 103-125), the atypical TRX domain (amino acid 167-176 
170, Ser-Asn-Asp-Cys, SNDC), the ER intraluminal C-terminal domain (amino acid 126-296) and a Di-177 
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lysine ER retention motif (amino acid 293-296, Lys-Lys-Asp-Lys, KKDK)3; 4. It has been suggested that 178 
TMX2 is enriched at the MAM location10. Because TMX2 does not contain a typical thioredoxin-like 179 
active domain (SNDC instead of CXXC), its oxidoreductase activity and role in protein folding have 180 
been questioned. However, the importance of TMX2 is underlined by the non-viability of 181 
homozygous Tmx2-/- knockout mice (C57BL/6NJ strain, Mouse Genome Informatics MGI:1914208). 182 
Here we report microcephaly, polymicrogyria (PMG), complex migration disorders and epilepsy in 183 
individuals bearing bi-allelic autosomal recessive variants in TMX2. We study the function of normal 184 
TMX2 and the effect of the variants in human cells providing a mechanistic understanding of TMX2 185 
function in health and disease, linking PDIs to neurodevelopment. 186 
MATERIAL AND METHODS 187 
Ethics statement and biopsy  188 
The cohort of TMX2 affected individuals (here coded as P1 to P14) includes 10 families of which four 189 
were gathered through the European Network on Brain Malformations, Neuro-MIG (COST Action 190 
CA16118), five families through GeneMatcher23 and one family was earlier described in 191 
supplemental data from a cohort of undiagnosed individuals with malformations of cortical 192 
development24. All study participants or their legal caretakers gave written informed consent to 193 
participate in this study and for publication of images, according to Erasmus MC institutional review 194 
board requirements (protocol METC-2012387). Skin biopsies were sampled before the study for 195 
routine diagnostic purposes and used to isolate dermal fibroblasts using standard procedures. 196 
Fibroblasts were tested negative for mycoplasma infection. 197 
 198 
Neuropathology 199 
An autopsy including brain was performed after demise of individual P1 at 14 days of age and 200 
individual P10 at two days of age. The material was fixed in 4% formalin. Samples from frontal, 201 
parietal, temporal, and occipital lobes, deep nuclei, cerebellum, brain stem and spinal cord were 202 
submitted for histological evaluation. Paraffin-embedded samples were cut to a thickness of 5 µm 203 
and hematoxylin and eosin-staining (H&E) or Lugol-PAS staining were performed according to the 204 
ŵaŶufaĐtuƌeƌ͛s guideliŶes ;HoffŵaŶŶ-LaRoche, Basel, Switzerland). For the age- and gender 205 
matched control brain, the sample collection was approved by the Institutional Ethical Review Board 206 
(EP02/21AG) of the Clinical Hospital Centre and School of Medicine, the University of Zagreb, in 207 
accordance with the Helsinki declaration 2000, and became a part of the Zagreb Neuroembryological 208 
Collection25. 209 
 210 
Genomic and Transcriptomic analysis 211 
Whole exome sequencing (WES) 212 
DNA was isolated from blood of the probands and family members and used for exome and Sanger 213 
sequencing, in nine different laboratories. WES data are deposited internally at the Erasmus MC and 214 
in each medical institute referring the individuals with TMX2 variants, in respect to the privacy of the 215 
families. Details of sequencing and analysis pipelines are described in the Supplemental data.  216 
 217 
RNA sequencing 218 
Skin fibroblasts from affected individuals P1, P2 and four different healthy age and sex (male) 219 
matched controls were cultured to 80% confluence in T175 flasks, befoƌe ‘NA isolatioŶ ǁith T‘Izol™ 220 
Reagent (Invitrogen®, 15596026) and RNA cleanup with RNeasy mini kit (Qiagen®, 74106). The 221 
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NEBNext Ultra Directional RNA Library Prep Kit for Illumina was used to process the samples. Strand-222 
specific mRNAseq libraries for the Illumina platform were generated with a poly-A selection and 223 
sequenced at GenomeScan (GenomeScan, Leiden, The Netherlands). Fastq files from forward and 224 
reverse reads were aligned to reference genome hg38 with the STAR aligner tool (v.2.4.2a)26. Counts 225 
per gene were calculated from bam files using the featureCount program with version 27 of the 226 
genecode hg38 annotation27. For differential gene expression P1 and P2͛s samples were compared 227 
to four male control samples in R (v.3.4.3) (R Core Team (2017). R: A language and environment for 228 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria) using the edgeR 229 
package (v.3.20.9)28. Functional annotation clustering of the top 1000 differentially expressed genes 230 
(p<0.05) was performed with gene ontology Database for Annotation, Visualization and Integrated 231 
Discovery (DAVID, v6.8)29; 30. Downstream affected biological functions were determined with 232 
Ingenuity Pathway analysis (IPA, Qiagen®, vs.2018) on all differentially expressed genes with a p-233 
value below 0.05. 234 
qPCR 235 
Skin fibroblasts were cultured in T75 culture flasks, in DMEM with 10% Fetal Calf Serum (FCS), 1% 236 
PenStrep, Lonza® (DMEM with serum), to 80% confluence. Total RNA was extracted on RNeasy mini 237 
columns (Qiagen®, 74106) according to the manufactureƌ͛s pƌotoĐol. ‘eǀeƌse tƌaŶsĐƌiptioŶ ǁas 238 
performed on 1 µg of RNA in a total volume of 20 µl, with the iScript cDNA Synthesis kit (Bio-Rad 239 
Laďoƌatoƌies®Ϳ used aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. ‘eal tiŵe ƋuaŶtitatiǀe PolǇŵeƌase 240 
Chain Reaction (RT-ƋPC‘Ϳ ǁas peƌfoƌŵed usiŶg iTaƋ™ UŶiǀeƌsal SYB‘® GƌeeŶ Supeƌŵiǆ ;Bio‘ad®Ϳ 241 
aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. Pƌiŵeƌs foƌ ‘T-qPCR analysis for the experiments shown in 242 
Fig. 3 are listed in Table S1. 243 
 244 
Antibodies  245 
Primary antibodies used: Polyclonal Rabbit anti-human TMX2 (HPA040282, Sigma®, WB 1:250), 246 
Monoclonal Rabbit anti-human HSP60 (D6F1, Cell Signaling®, Immunocytochemistry (ICC) dilution 247 
1:800), Monoclonal Rabbit anti-human CNX (C5C9, Cell Signaling®, ICC 1:50, IP 1:1000), Mouse 248 
monoclonal anti-SERCA2 ATPase (ab2861, Abcam IP:1:1000), Mouse monoclonal anti-Myc (9B11, 249 
Cell Signaling Technologies®, WB 1:3000 and ICC 1:500), Mouse monoclonal anti-PDI (1D3, ADI-SPA-250 
891, Enzo Life Sciences, WB: 1:1000) 251 
Secondary antibodies used for ICC: Green Goat anti-Rabbit IgG (H+L) Alexa Fluor 488 (1:400, Thermo 252 
Fisheƌ SĐieŶtifiĐ®, AϭϭϬϴϴͿ, ‘ed CǇ™ϯ AffiŶiPuƌe DoŶkeǇ AŶti-Mouse IgG (H+L) (1:100, Jackson 253 
Laboratories®, 715-165-150). Secondary antibodies used for WB in 1 in 10 000: Red IRDye® 680RD 254 
Goat anti-Rabbit IgG (H + L) (LI-COR Biosciences®, 926-68071), Green IRDye® 800CW Goat anti-255 
Mouse IgG (H + L) (LI-COR Biosciences®, 926-32210). 256 
 257 
Plasmid constructs 258 
Wild-type human TMX2 (NM_015959) was cloned in a pCMV-Entry-Myc-DDK TrueORF Gold vector 259 
(OriGene®, RC200032). 50 µL semi-competent homemade Escherichia coli XL10-Gold Bacteria strains 260 
were thawed on ice for 20 minutes and subsequently incubated for 15 minutes with 0.1 µg wild-type 261 
TMX2 plasmid. Transformation of the bacterial cells was induced through a heat shock at 42°C for 2 262 
minutes. 800 µL Luria-Bertani (LB) broth (EZ™ Mix, Lennox®) was added to the cells and placed under 263 
agitation (200 rpm, 40 min, 37°C). Selection of transformed cells was performed overnight on LB-264 
Kanamycin agar plates at 37°C. Vector-positive colonies were grown to 50 mL midiprep. Plasmid DNA 265 
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was isolated with the Qiagen® Plasmid Plus Midi kit. The full length and sequence of TMX2 cDNA in 266 
the plasmid was checked by capillary sequencing before performing the transfections. 267 
pĐDNA™ϯ.ϭ/Myc-His (-)/LacZ (Thermo Fisher Scientific®) was used as a negative control and kindly 268 
provided by Dr. Mark Nellist.  269 
 270 
Site-directed Mutagenesis (SDM) 271 
Variant TMX2 constructs (TRX domain SNDC to SNDG p.Cys170Gly and affected iŶdiǀiduals͛ ǀaƌiaŶts 272 
p.AƌgϱϯCǇs aŶd p.AƌgϮϯϭTƌpͿ ǁeƌe geŶeƌated aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌs͛ pƌoĐeduƌes usiŶg the 273 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent®), wild-type purified TMX2 construct dilution 274 
(10 ng/µL) and 100 ng/µL primers specified in Table S2. PCR products were transformed in 275 
ultracompetent Escherichia coli XL10-Gold ďaĐteƌia suppleŵeŶted ǁith β-mercaptoethanol in SOC 276 
medium through a heat shock at 42°C for 30 seconds. Selection, midi isolation and Sanger 277 
sequencing were performed in analogy with the wild-type construct. 278 
 279 
Sanger sequencing of plasmid DNA 280 
Sanger sequencing of wild-type and variant plasmid DNA was performed as earlier described31. 281 
BƌieflǇ, aŵplifiĐatioŶ ƌeaĐtioŶs ǁeƌe peƌfoƌŵed iŶ a total ǀoluŵe of ϮϬ μl, ĐoŶtaiŶiŶg ϭ× PC‘ ďuffeƌ 282 
ǁith Mg ;‘oĐheͿ, ϮϬϬ μM of eaĐh dNTP, ϭ μM foƌǁaƌd aŶd ƌeǀeƌse pƌiŵeƌ ;speĐified iŶ Taďle SϯͿ, Ϭ.ϭ 283 
units Fast Start Taq DNA polymerase (Roche), and 25 ng genomic DNA. PCR conditions were as 284 
folloǁs: ϱ഻ ϵϲ°C, ϭϬ ĐǇĐles of ϯϬ഼ ϵϲ°C, ϯϬ഼ ϲϴ°C ;−ϭ°C/ĐǇĐleͿ, ϲϬ഼ ϳϮ°C, folloǁed ďǇ Ϯϱ ĐǇĐles of ϯϬ഼ 285 
ϵϲ°C, ϯϬ഼ ϱϴ°C, ϲϬ഼ ϳϮ°C, aŶd a fiŶal eǆteŶsioŶ foƌ ϱ഻ ϳϮ°C.  286 
PCR reactions were purified with ExoSAP-IT (USB). Direct sequencing of both strands was performed 287 
with Big Dye Terminator chemistry (version 3.1; Applied Biosystems). DNA fragment analysis was 288 
performed with capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems) with 289 
the software package Seqscape (Applied Biosystems, version 2.1). 290 
 291 
Transfection 292 
Human Embryonic Kidney HEK293T cells were plated at 5x104 cells/cm2 with or without 24 mm cover 293 
slips (Thermo Fisher Scientific®) cultured in 2mL DMEM with serum in a 6 well plate or 10 cm petri 294 
dishes for immunoprecipitation. The next day culture media was replaced with 2 mL DMEM without 295 
serum (Lonza®). Per 10 cm2, 1 µg plasmid DNA was added to 125 µL DMEM without serum at room 296 
temperature and 3 µL/10cm2 LipofeĐtaŵiŶe™ ϮϬϬϬ TƌaŶsfeĐtioŶ ‘eageŶt ;Thermo Fisher Scientific®) 297 
was added to 125 µL DMEM without serum. These tubes mixed and incubated 5 minutes at room 298 
temperature, prior to transfection. The appropriate volume was added to each dish in a dropwise 299 
manner. After 3 hours, 10% FCS and 1% PenStrep was supplemented to the dishes. After 24h 300 
transfection, cells were fixated with methanol for 10 minutes at -20°C or lysed for western blot and 301 
immunoprecipitation. Transfection was also stable after 48 and 72h (Fig.S3). 302 
 303 
Immunoprecipitation (IP) and Mass spectrometry (MS) 304 
Exogenous TMX2 was immunoprecipitated after transfection in HEK293T cells. Initially, 15 µL EZview 305 
Red Anti-c-Myc Affinity Gel beads (E6654, Sigma Aldrich®) were washed with non-denaturing TNE-306 
1% lysis buffer (50mM Tris pH 7.6 + 100mM NaCl + 50mM NaF + 1% NP-40 + 1mM EDTA + Protease 307 
inhibitor tab Roche®). TMX2-transfected and control Lac-Myc-transfected HEK293T cells in 10 cm 308 
Petƌi͛s dishes ǁeƌe tƌaŶsferred on ice, washed with 1×dPBS, and lysed with 800 µL TNE-1% lysis 309 
buffer. To test transfection efficiency and localization, each dish contained a 24 mm coverslip, which 310 
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was subsequently fixated and immunostained, before adding the lysis buffer. Lysates were 311 
incubated on ice for 10 minutes and centrifuged at 10000 x g for 10 minutes at 4°C. The supernatant 312 
was added to the washed beads and incubated overnight under agitation at 4°C. After washing 3 313 
times with TNE-1% lysis buffer and centrifugation at 1000 x g, 15 sec, 4°C, bead pellets were 314 
subjected to a Mass spectrometry preparation as described32. Protein Mascot scores and numbers of 315 
unique peptides were taken directly from the Mascot output and reported. Only hits with a Mascot 316 
score higher than 40 were taken into account for analysis. 317 
Mitochondrial respiration and glycolysis determination 318 
Bioenergetics profiles of human primary skin fibroblasts were generated in real time with a Seahorse 319 
XF24 Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, Ca, USA) as previously 320 
described33. Fibroblasts were seeded on a Seahorse XF-24 plate at a density of 6×104 cells per well 321 
and grown overnight in DMEM with serum at ϯϳ ˚C, ϱ% CO2. This density ensures a proportional 322 
response to the uncoupler FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) with cell 323 
number and resulted in confluent cultures, in which cell replication was further prevented by 324 
contact inhibition. On the experimental day, medium was changed to unbuffered DMEM (XF Assay 325 
Medium – Agilent Technologies, Santa Clara, Ca, USA) supplemented with 5 mM glucose and 1 mM 326 
sodium pyruvate, and incubated 1 hour at 37 °C in the absence of CO2. Medium and reagent acidity 327 
was adjusted to pH 7.4 oŶ the daǇ of the assaǇ, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌoĐeduƌe. 328 
Mitochondrial respiration was measured as the oxygen consumption rate (OCR), and glycolysis was 329 
measured as the extracellular acidification rate (ECAR). After three baseline measurements for the 330 
oxygen consumption ratio (OCR), cells were sequentially challenged with injections of mitochondrial 331 
toxins: 0.5 µM oligomycin (ATP synthase inhibitor), 1 µM FCCP (mitochondrial respiration 332 
uncoupler), 0.5 µM rotenone (complex I inhibitor), and 0.5 µM antimycin (complex III inhibitor). 333 
For galactose experiments, cells were cultured in galactose 10 mM, 10% FCS, 2 mM glutamine, 5 mM 334 
Hepes and 1% penicillin-streptomycin medium for three days before the bioenergetics assay33.  335 
A minimum of two Seahorse replicates were performed for each fibroblast line. In each replicate, we 336 
used six wells for each line. In each run, six wells were always used for a reference primary fibroblast 337 
line with highly characterized bioenergetics behavior. Three reference lines that were available at 338 
the Erasmus MC institute have been used33.  339 
Basal respiration was defined as the average OCR values at baseline. Respiration dedicated to ATP 340 
production was calculated as difference between basal respiration and the respiration measured 341 
after oligomycin injection. Reserve capacity was calculated as the difference between the maximal 342 
respiration (the average OCR of the three measurements following the FCCP injection) and basal 343 
respiration. The rotenone dependent respiration parameter was calculated as the difference 344 
between the maximal respiration value and the average OCR values obtained after the rotenone 345 
injection and was used to evaluate the activity of mitochondrial complex I. Basal glycolysis was 346 
defined as the average of the 3 baseline ECAR measurements, and the increase in glycolysis after 347 
blocking ATP synthase was indicated as oligomycin stimulated glycolysis.  348 
 349 
TMX2 Redox state assay 350 
HEK293T cells were transfected during 24 hours with plasmid DNA producing Myc-tagged β-351 
lactamase control protein (Lac-Myc), wild-type (TMX2) or variant TMX2 (p.Cys170Gly, p.Arg53Cys 352 
and p.Arg231Trp) in a 6 well plate. Afterwards cells were treated with different ER-stress inducers or 353 
oxidant/reductant at 37°C with 5% CO2, according to Matsuo et al 34: 6h with 0,5 µg/mL Brefeldin A 354 
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(BFA; Cayman Chemical® CAS 20350-15-6, 20 mg/mL stock in DMSO), 6h with 5 µM Thapsigargin (TG, 355 
Sigma® T9033, 1mM stock in DMSO), 6h with 10 µg/mL Tunicamycin (TM, Sigma® T7765, 1mg/mL 356 
stock in DMSO), 10 minutes with 5 mM DL-Dithiothreitol (DTT, Fluka® CAS 3483-12-3, 100 mM stock 357 
in MilliQ sterile water), or 10 minutes with 200 µM Hydrogen peroxide H2O2 (Merck®, 822287). Free 358 
thiol groups were alkylated by washing and 10 min incubating the cells with ice-cold 1× dPBS (Sigma 359 
Aldrich®) supplemented with 20 mM N-ethylmaleimide (NEM, Sigma®, E3876-5G) and 4× Laemmli 360 
buffer (3:1) before storage at -20°C. Total protein concentrations were determined by a BCA 361 
pƌotoĐol ǁith VaƌioskaŶ™ LUX ŵultiŵode ŵiĐƌoplate ƌeadeƌ ;Theƌŵo Fisheƌ SĐieŶtifiĐ®Ϳ. EƋual 362 
protein concentrations were loaded onto a 4-ϭϱ% CƌiteƌioŶ™ TGX StaiŶ-Fƌee™ PƌoteiŶ Gel ;Bio-Rad 363 
Laboratories®). Proteins were separated in a non-reducing SDS-PAGE ǁith a CƌiteƌioŶ™ Cell geltaŶk 364 
(Bio-Rad Laboratories®) at 100 Volt for 1h40min in Tris-Glycine-SDS running buffer. Proteins were 365 
transferred by wet blotting to a Nitrocellulose membrane (Amersham Protran 0.45 NC, GE 366 
Healthcare Life Sciences®) at 100 Volt for 1h at 4°C or alternatively on a Trans-Blot Tuƌďo Ϭ.Ϯ μŵ 367 
Nitrocellulose membrane (BioRad®) at 25V, 1.5A for 20 minutes in a Trans-Blot Turbo transfer 368 
system (BioRad®). After antibody incubation, bands were detected with a fluorescent based 369 
approach on the Odyssey Infrared Imager (LI-COR Biosciences®). Densitometry analysis to determine 370 
Dimer/monomer ratios was performed in Odyssey 3.0 Software or Image Studio Lite Version 5.2.  371 
Statistics 372 
Statistical tests were performed with GraphPad 8 and are specified in legends of the experiments. 373 
 374 
RESULTS 375 
Clinical overview  376 
The clinical features observed in all fourteen individuals, in whom we detected TMX2 variants, have 377 
been summarized in Table 1 and full clinical and MRI description is available in the Supplemental 378 
Note, Table S4 and Figure 1. Most subjects (11/14) were reported with microcephaly (defined as 379 
OFC at or below -2.5 SD, for age and sex; Table 1) and, where documented, this was present at birth 380 
or at the first clinical examination. However, intra-familial discrepancy is present, because only one 381 
of the two siblings of family 5 was microcephalic at adult age (P5), while the other sibling has a 382 
borderline normal head circumference (P4) in the third decade of life.  Two other affected 383 
individuals of family 9 and 10 did not present with microcephaly at the last examination (Table 1, 384 
P13 and P14). With the exclusion of two individuals (P6 and P14), all have suffered from drug-385 
resistant epilepsy, occurring in most cases in early infancy, characterized by apnea, epileptic spasms, 386 
myoclonic seizures, focal seizures with or without secondary generalization, generalized tonic clonic 387 
(GTC) seizures and in one case possible diaphragmatic myoclonia. Three affected individuals of the 388 
cohort died during infancy, two of them of severe epilepsy in the early post-natal period. The brain 389 
imaging of these two is strikingly similar (Figure 1, P1 and P10) and resembles a congenital viral 390 
(CMV) infection for the presence, besides diffuse bilateral polymicrogyria (PMG), of reduced central 391 
white matter volume, abnormal appearance of the periventricular borders with an occipital 392 
pseudocyst. In both cases no infection was documented, and brain pathology excluded the presence 393 
of inflammatory signs. All subjects, but one (Family 10, P14) surviving beyond infancy present with 394 
severe developmental delay (Table 1), progressing to profound intellectual disability, cerebral palsy 395 
with absent ambulation and lack of speech and/or progressive neurodegenerative course. No 396 
additional extra-CNS malformations or health issues were observed, except for expected 397 
complications of the underlying brain pathology. Metabolic screening performed in most subjects 398 
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did not reveal abnormalities of intermediate or energy metabolism. Two individuals have been 399 
followed in their third decade (P4 and P5): they both showed signs of regression, with loss of motor 400 
skills and severely impaired cognitive skills and no speech development.  401 
Structural brain abnormalities were detected in almost all the subjects undergoing MRI scan. In 402 
seven of the twelve affected individuals who received an MRI scan (Figure 1) a cortical malformation 403 
has been documented.  Diffuse PMG (small and excessive number of gyri) was observed in five 404 
individuals (Figure 1, P1, P2, P3, P10 and P12), while the two siblings from family 5 show diffuse 405 
pachygyric (= thickened and smooth) cortex (Figure 1, P6-P7). The brain imaging of these latter 406 
siblings had been reported in supplemental data from a cohort of undiagnosed individuals with 407 
malformations of cortical development24. In three other individuals brain imaging shows 408 
(progressive) global cerebral atrophy (families 4 and 6). The two remaining affected individuals 409 
showed an MRI with no cortical malformation (P14) or a hemihypertrophy with frontal dysgyria 410 
(P13). No brain imaging was performed in individual P8 (Family 6) and individual P11 (Family 8). 411 
Brain pathology of affected individuals (P1 and P10) 412 
At autopsy of individual P1 (day 14 postpartum), the head circumference was 34 cm (-2SD) and the 413 
brain weight 316 g (normal weight at term: 400-450 g). Macroscopically, the brain surface was 414 
polymicrogyric with the temporal regions being least affected (Figure 2A and 2B).  415 
Evaluation of H&E stained sections of the frontal, parietal, temporal and occipital cortex showed 416 
extensive unlayered polymicrogyria throughout the sampled cortical sections (Figure 2E and 2F). 417 
Undulating bands of neurons extended deeply in the cortex. The insular and parahippocampal region 418 
were least affected with undulating neuronal bands extending less deep into the cortex. The 419 
hippocampus was spared. The transition from normal cortex to polymicrogyric cortex was abrupt. 420 
The molecular layer appeared fused between adjacent gyri causing inclusions of pial vessels in the 421 
deep cortical region. Leptomeninges overlying the polymicrogyric cortex were focally thickened. 422 
Overmigration of neurons into the arachnoid space was not noted. The grey-white matter junction 423 
was blurred under affected cortical areas. The white matter was normal. Heterotopic remnants of 424 
the germinal matrix were occasionally observed in the periventricular region which is considered 425 
pathologic given that the affected individual was born at term. Telangiectatic vessels were present in 426 
the brain stem at the level of the locus coeruleus. Histologically, other brain structures and the eyes, 427 
especially the retina appeared normal. There were no signs of mitochondrial disease or an acquired 428 
cause for the malformation, e.g. no calcifications or inflammatory cells. The basal ganglia were 429 
normal as well as the cerebellum, which consisted of a four-layered cortex including the for the age 430 
appropriate external granular layer. 431 
Brain examination of individual P10 (Figure 2C) macroscopically showed a polymicrogyric cortex of 432 
the occipital lobes, but microscopically the whole cerebral cortex was polymicrogyric, with diffuse 433 
dyslamination, fusion of molecular layers and blurred grey-white matter junction (Figure 2G). In 434 
contrast with P1, in the polymicrogyric areas glioneuronal heterotopia were diffusely seen migrating 435 
over the meninges iŶ PϭϬ͛s ďƌaiŶ.  In the frontal area few calcifications were seen at the grey-white 436 
matter border, with some calcification of the pericallosal artery, without any other evidence for 437 
(focal) infection or inflammation. The occipital ependymal layer showed interruptions and gliotic 438 
changes with some reactive macrophages. The presence of neuroglial cells migrating over the glia 439 
limitans of the pia into the arachnoid space is typical of the cobblestone malformation. However, 440 
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there were no additional abnormalities common in the cobblestone malformation, such as 441 
brainstem and cerebellar hypoplasia35. 442 
 443 
Genomic and Transcriptomic analysis 444 
Biallelic variants in TMX2 were identified in fourteen affected individuals from ten unrelated 445 
pedigrees by whole exome sequencing (WES), compatible with autosomal recessive inheritance. 446 
Detailed information on the genomic alterations (cDNA alteration, protein alteration, gnomAD 447 
frequency, SIFT, MutationTaster and CADD scores) are described in Table S4 and Supplemental 448 
Results and a schematic overview of the gene and the thirteen discovered variants can be found in 449 
Figure 3A. TMX2 encodes a transcript of 8 exons (NM_015959.3), which is translated into a protein 450 
with 296 amino acids. To test the effect of each variant on TMX2 mRNA expression transcriptomic 451 
analysis was performed.   RT-qPCR in skin fibroblasts from the affected newborn P1 of Family 1 with 452 
a compound heterozygous mutation in TMX2 (c.164A>C, p.Asp55Ala; c.391dup, p.Leu131Profs*6), 453 
showed that TMX2 mRNA expression was much lower (nearly half fold), compared to healthy 454 
controls (Figure 3 B). To determine which of the alleles was still expressed, we performed allele 455 
specific RT-qPCR (primers specified in Table S1). Results showed that the allele carrying the 456 
frameshift in exon 4 barely expressed any product (2-3% of total level TMX2 mRNA in healthy 457 
controls), indicating that very likely the transcript is subjected to nonsense mediated decay (NMD) 458 
(Figure 3C). When amplifying the other allele, total TMX2 mRNA expression was again reduced to 459 
approximately half, confirming our previous result (Figure 3B) and showing that the allele with the 460 
c.164A>C, p.Asp55Ala variant is normally expressed (Figure 3C). 461 
In Family 2, the proband (P2) had a homozygous TMX2 missense change in the ultimate nucleotide 462 
of exon 6 (c.614G>A, p.Arg205Gln), with a predicted effect on splicing. RT-qPCR did not show 463 
significant decrease in expression of TMX2 mRNA in skin fibroblasts from the proband, compared to 464 
healthy controls (Figure 3B). However, since the variant affected the last nucleotide of an exon, an 465 
effect on mRNA splicing was suspected. We used RNAseq in combination with Integrated Genomics 466 
Viewer (IGV) to visualize cumulative transcript reads per exon in a Sashimi plot (Figure 3D) and the 467 
amount of reads per million were calculated (Figure 3E). The c.614G>A, p.Arg205Gln variant indeed 468 
affected splicing through introduction of a new internal splice site in exon 6, resulting into four 469 
different transcripts: regular mRNA, an alternative transcript with a loss of 11 nucleotides within 470 
exon 6, an alternative transcript with full in-frame exon 6 skipping (loss of 66 nucleotides) and mRNA 471 
with intron 6 retention (Figure 3E). This latter transcript is also present at low level in healthy 472 
controls. Individual reads of each transcript are shown in Figure S1. 473 
In Family 3, individual P3, similar to the variants in individual P1, a combination was found of a 474 
missense change in exon 1 (c.157C>T, p.Arg53Cys, nearby the p.Asp55Ala of P1, together with a 475 
nonsense variant leading to a premature stop codon in the last exon of TMX2 (c.757C>T, p.Arg253*). 476 
The effect of the variants on TMX2 transcription in skin fibroblasts was tested. RT-qPCR showed a 477 
mean decreased level of TMX2 mRNA expression by 23%, potentially indicating that the premature 478 
termination codon in the last exon of the transcript partially escapes nonsense mediated decay, as 479 
being less than 50 to 55 nucleotides fƌoŵ the stop ĐodoŶ at the ϯ͛-end (for TMX2 nt836-891) (Figure 480 
3B)36. 481 
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For families 4 to 10 no materials were available to test the transcriptional effect of each variant. 482 
However, considering lethality in Tmx2 null mice, residual TMX2 transcript can be anticipated 483 
originating from the missense alleles and/ or the allele creating a new splice acceptor site (P10).   484 
Gene ontology (GO) analysis of differentially expressed genes in TMX2 pathogenic variants  485 
Our data clearly indicates that biallelic TMX2 variants lead to reduced TMX2 expression, acting as 486 
loss of function variants (LoF) (Figure 3). Compared to other TMX family members, only TMX2 is 487 
expressed steadily from week 8 throughout fetal brain development, even increasing during 488 
postnatal life (mRNA expression during human brain development retrieved from Allen human brain 489 
atlas Figure S3). We therefore considered the TMX2 variants as probably explanatory for the early 490 
neurological manifestation and decided to investigate their effect in detail. 491 
We performed analysis of RNAseq data from cultured skin fibroblasts of two affected individuals (P1 492 
and P2), in parallel with three age and gender matched controls, and studied which pathways were 493 
deregulated.  494 
Functional annotation clustering analysis  495 
Functional annotation clustering analysis of the top 1000 significant differentially expressed genes 496 
(DEGs) (p<0.05), by the Database for Annotation, Visualization and Integrated Discovery (DAVID, 497 
v6.8) ranked the top cluster of genes as those associated with post-translational modifications, i.e. 498 
intramolecular or intermolecular disulfide bond formation (Annotation Cluster 1: Disulfide bond p = 499 
9.9x10-24) and N-linked glycosylation (Annotation Cluster 1: Glycoprotein p= 2.1x10-28 and 500 
Glycosylation site:N-linked p=2.5x10-27) (Figure 4A). From this cluster of genes, 24 disulfide 501 
containing genes were subtracted as being the highest deregulated of this cluster in cells from 502 
affected individuals, having a False Discovery Rate (FDR) lower than 0.05 (Figure 4B). Stringent 503 
filtering (FDR<0.01) without clustering, uncovered 37 differentially expressed genes of which five 504 
were indirectly controlled by the UPR or regulate expression of UPR markers, i.e. CXCL5 (OMIM 505 
600324) 37, DAPK1 (OMIM 600831) 38, HGF (OMIM 142409) 39, LTBP1 (OMIM 150390) 40 and CES1 506 
(OMIM 114835) 41. Interestingly, the second highest deregulated gene LTBP1 encodes a known 507 
folding substrate for another PDI protein, ERp46, also known as TXNDC542; 43. Although it has been 508 
suggested that most PDIs show substrate specificity2, LTBP1 could also be a substrate of TMX2 or 509 
TMX2 might affect TXNDC5 mediated folding. 510 
The second most significant functional annotation cluster ranks genes having a transmembrane 511 
domain (Enrichment score= 9.43) and a third most significant cluster contains genes encoding 512 
proteins involved in synaptic function, specifically located at the postsynaptic membrane 513 
(Enrichment Score= 4.63). This latter membrane is enriched with receptors and ion channels, 514 
essential for the interaction with neurotransmitters. Interestingly, another cluster mentions the 515 
deregulation of calcium ion binding (Annotation Cluster 6 Enrichment score 3.16). 516 
 517 
Ingenuity pathway analysis (IPA) 518 
Ingenuity pathway analysis (IPA) of the same differentially expressed genes in cells from the two 519 
probands (p<0.05), taking into account the logarithmic Fold Change (LogFC) of each gene, was used 520 
to calculate the most affected biological functions and diseases networks (Figure 4C). Only activation 521 
Z-scores in the 90 percent confidence interval were considered to be significant (Z[−∞,-1.65] and 522 
Z[1.65, +∞]). Interestingly, this analysis showed two key IPA categories being inhibited in TMX2 523 
affected individuals, i.e. ͚Nervous System Development and Function͛ aŶd ͚Cellulaƌ Gƌoǁth, 524 
PƌolifeƌatioŶ aŶd Suƌǀiǀal͛ (Blue bars in Figure 4C). The most significant inhibited function was 525 
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͚ƋuaŶtitǇ of ŶeuƌoŶs͛ ;)=-2.864), with a decreased outgrowth of cells (Z= -2.818), specifically neurons 526 
(Z=-2.594) and neurites (Z= -2.46), all related to processes affected in microcephaly. Consequently, 527 
transcripts related to learning ability (Z= -2.356) and cognition function (Z= -2.257) were also shown 528 
to be potentially decreased in cells from affected individuals. Moreover, besides the development of 529 
neurons (Z= -1.955), the differentiation of neurons was highly inhibited(Z= -1.812). Lastly, overall cell 530 
survival (Z= -1.785) and viability (Z= -2.016) were decreased. When looking at the most activated 531 
biological functions or associated diseases, seizures (Z=2.712) and seizure disorder (Z=2.819) are the 532 
most significant activated features (Red bars in Figure 4C).  533 
Proteomics analysis of exogenous TMX2 534 
In view of the effect of TMX2 variants on transcriptome, specifically on disulfide bond formation, we 535 
wondered whether TMX2 functions as an oxidoreductase and/or chaperone in protein folding. A 536 
transfection protocol was optimized in HEK293T cells with a Myc-tagged vector containing full length 537 
TMX2 sequence (p.CMV6.TMX2-Myc/DKK) and a Myc-tagged β-lactamase vector as negative control 538 
(pĐDNA™ϯ.ϭ/Myc-His (-)/LacZ). Immunocytochemistry of exogenous TMX2 localized the protein to 539 
the MAM through co-localization with the marker Calnexin (CNX) (Figure S4 A) and in the vicinity of 540 
the mitochondria, visualized by mitochondrial marker HSP60 (Figure S4 B). Next, we aimed at the 541 
identification of the TMX2 interacting proteins, by performing mass spectrometry-based proteomics 542 
of co-precipitated proteins. A 24-hour over-expression of Myc-tagged TMX2, followed by 543 
immunoprecipitation and LC-MS/MS reveals 71 unique peptides as putative interactors. The list of 544 
reproducible co-precipitated proteins is shown in Table S5 and visualized with Cytoscape String App 545 
according to pathway involvement in Figure 5A. A first interesting observation was that TMX2 546 
physically interacts with MAM marker CNX, which is a calcium-binding protein folding chaperone. 547 
Other PDIs have also been shown to bind with CNX, e.g. TMX12, TMX46, ERp572. Binding was 548 
reciprocally confirmed after IP of CNX and detection of Myc-tagged TMX2 on western blots (Figure 549 
5B). Besides CNX, multiple other protein folding regulators and ER chaperones were interacting with 550 
TMX2 (Figure 5, dark blue), i.e. co-chaperones of the HSP70 family DNAJA2(HSP40) and BCL2 551 
associated athanogene 2(BAG2), chaperonin containing TCP1 subunit 5 (CCT5), Translocon-552 
associated protein/TRAP subunit alpha (SSR1), N-glycosylation regulators glucosidase II alpha subunit 553 
(GANAB) and Dolichyl-diphospho-oligosaccharide-protein glycosyltransferase complex (OST 554 
complex: RPN2, DDOST, STT3B, MLEC)44.  555 
 556 
Furthermore, besides CNX, TMX2 bound with other key-regulators of calcium homeostasis, i.e. Ca2+-557 
binding proteins (RCN2, HAX1, SSR1) and Ca2+-ion channels located at the MAM or mitochondrial 558 
membrane (ATP2A2/SERCA2, VDAC1) (Figure 5A, light blue). TMX2 also binds to Erlin-2 which 559 
directly regulates inositol 1,4,5-trisphosphate Ca2+ receptor degradation. These calcium receptors 560 
and channels are necessary for mitochondrial bioenergetics. SERCA2, like CNX, is a main interactor of 561 
some PDI members (TMX17, ERdj51) and described as a key regulator of protein folding. Binding was 562 
confirmed reciprocally after immunoprecipitation of SERCA2 and detection of Myc-tagged TMX2 on 563 
western blot (Figure 5B). Proteomics data also indicates physical interaction of TMX2 with 564 
components of mitochondrial outer and inner membrane complexes (Figure 5A, green), e.g. the 565 
mitochondrial contact site and cristae organizing system (MICOS, MIC60/IMMT subunit), the 566 
mitochondrial precursor protein import pathways (TOM22 and TIM23 complex)45, and the 567 
mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I NDUFA2 and NDUFA12 568 
subunits). 569 
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TMX2 also interacted with proteins regulating the unfolded protein response, i.e. DDRGK1, a direct 570 
regulator of I‘Eϭα-XBP1 and PERK-eIFϮα-CHOP signaling46, or the UPR associated endoplasmic 571 
reticulum-associated degradation (ERAD), dependent on an ubiquitin-proteasome system (UPS) 572 
(Figure 5, red), i.e. TMX2 binds with VCP-AMFR ERAD complex, Erlin-2 involved in ERAD of IP3Rs, 573 
Ubiquitin-binding protein UBXN1, deubiquitinating enzyme USP25, and proteasome subunits 574 
PSMD2, PSMD3 and PSMA5. Because of these interactions, the RNAseq showing dysregulated genes 575 
indirectly linked to UPR signaling and the role of TMX2 in protein folding, we tested the hypothesis 576 
whether TMX2 variants activated the UPR, specifically the I‘Eϭα-XBP1 and PERK-eIFϮα-CHOP 577 
signaling. RT-qPCR of UPR downstream mRNA markers CHOP and spliced XBP1 was performed for 578 
the three available fibroblasts lines derived from affected individuals and showed that aberrant 579 
TMX2 did not affect the amount of expressed sXPB1, nor CHOP (data not shown). Although the 580 
RNAseq data of affected individuals showed DEGs indirectly linked to the UPR, no direct factors of 581 
any of the three UPR pathways were found to be upregulated when TMX2 was mutated. Hence, 582 
together these data indicate thatTMX2 pathogenic variants do not lead to constitutive UPR 583 
activation in fibroblasts from affected individuals. 584 
 585 
Mitochondrial bioenergetics in TMX2 variant fibroblasts 586 
PDIs and protein folding are important determinants for normal mitochondrial bioenergetics and cell 587 
survival. In view of the putative function of TMX2 at the ER-MAM-mitochondria interface, the results 588 
of RNAseq (hinting towards a deregulated disulfide bond formation and calcium binding in cells from 589 
affected individuals) and proteomics analysis (showing binding with regulators of protein folding, 590 
ERAD, ER-mitochondrial UPR and Calcium homeostasis), we focused on mitochondrial activity and 591 
evaluated mitochondrial respiration and glycolytic activity in TMX2 variant fibroblasts derived from 592 
three affected individuals  (P1, P2 and P3) using a Seahorse Extracellular Flux Analyzer. Only P3 593 
showed reduced basal mitochondrial activity and reduced respiration dedicated to ATP production 594 
when compared to healthy control lines. At the same time, all TMX2 variant fibroblasts featured 595 
suppressed mitochondrial respiration upon stimulation with the mitochondrial uncoupler FCCP, with 596 
a significantly reduced reserve capacity – which reflects the bioenergetics reservoir available to 597 
counteract cellular stress - and overall decreased rotenone dependent respiration. The latter 598 
indicates a reduced activity of mitochondrial complex I (Figure 6A and 6C). Interestingly, P1 and P2, 599 
but not P3 showed a significant increase in the glycolytic activity – that was measured as lactate 600 
dehydrogenase mediated acidification of the medium- both in basal condition and upon stimulation 601 
with the mitochondrial ATP-synthase inhibitor oligomycin (Figure 6B and 6D), indicating that TMX2 602 
variant fibroblasts compensated the mitochondrial bioenergetics defects by potentiating the 603 
glycolytic pathway and glucose catabolism. Quantification of cellular ATP levels showed no 604 
differences between TMX2 affected individuals and controls (Figure S5). To identify potential 605 
mitochondrial defects silenced in glycolysis permitting conditions, we performed the experiments 606 
also in conditions where glycolysis was inhibited by the presence of galactose, forcing cells to rely on 607 
mitochondrial respiration for ATP production. As expected, P1 and P2 failed to potentiate basal 608 
respiration and showed no significant increase of respiration dedicated to ATP production and of 609 
mitochondrial complex I activity when cultured in galactose medium, although retained the ability to 610 
potentiate the reserve capacity (Figure 6E).  611 
 612 
Redox state analysis of wild-type and variant TMX2 613 
TMX2 oxidizes and reduces in native conditions 614 
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We tested whether thiol groups in TMX2 can be oxidized and reduced and thus whether TMX2 is 615 
able to form disulfides, hence would be able to influence protein folding. HEK293T cells were 616 
transiently transfected with TMX2 (Figure 7A) or β-lactamase vector (Figure 7B) and the redox state 617 
of TMX2 was monitored before and after treatment with the reducing agent DTT, the oxidant 618 
hydrogen peroxide (H2O2) or the ER-stress inducers: Brefeldin A (ER-Golgi transport blocker) (Figure 619 
7 A-B), Thapsigargin (SERCA2 inhibitor) or Tunicamycin (N-glycosylation inhibitor) (Figure 7C). To be 620 
able to distinguish redox state of cysteines, cells were incubated with a cysteine alkylating reagent 621 
N-ethylmaleimide (NEM) to covalently bind reduced thiol groups (+0.125kDa /thiol), but not oxidized 622 
disulfide groups. Figure 7A, lane 1 and 5, shows that TMX2 exists in both a reduced NEM alkylated 623 
form (~33 kDa) and an oxidized lower molecular form (~31 kDa) in native conditions. These two 624 
bands were consistently found in all of our repeat experiments with the ratios of oxidized and 625 
reduced TMX2 alternating, e.g. sometimes more reduced TMX2 (Figure 7A, lane 1), sometimes equal 626 
amount (Figure 7C, lane 1), and sometimes more oxidized TMX2. ER stress induced by BFA, 627 
tunicamycin or thapsigargin did not alter TMX2 redox state (Figure 7A, lane 2, 6 and Figure 7C lane 628 
2, 5, 6) Ŷoƌ its͛ pƌoteiŶ level. DTT treatment partially shifted redox state to a more reduced TMX2 629 
(Figure  7A, lane 3) and TMX2 was completely reduced in the presence of β-mercaptoethanol (Figure 630 
5B and S6), indicating that at least part of TMX2 redox state is thiol mediated. 631 
  632 
TMX2 dimerizes and oxidative stress elevates dimer/monomer ratio 633 
Surprisingly, H2O2-mediated oxidation of cells overexpressing TMX2 did not result in an increase of 634 
the lower oxidized TMX2 band, as we observed for PDI (PDIA1) (Figure 7A, lane 12), but generated 635 
an intense TMX2-reactive extra band with higher molecular mass on immunoblot  (Figure 7A, lane 4 636 
and 8;  apparent mass ~65kDa). Since molecular mass was double the amount of a TMX2 monomer, 637 
we hypothesize that this band represents a slower migrating homodimer.  Dimer/monomer ratios 638 
were calculated, showing up to a 200 fold increase of dimerization in oxidative environment (Figure 639 
7D, H2O2 p=0.0005). The dimer was still present when SDS-PAGE was performed in reducing 640 
conditions with β-mercaptoethanol and without NEM, although the ratio dimer/monomer was 641 
almost inverted and the monomer represented the major band (Figure S6). These results indicated 642 
that oxidative conditions mediated by H2O2, induce dimerization of TMX2 and that this dimerization 643 
is at least partially mediated by disulfide bond formation. Homodimerization was confirmed through 644 
linear correlation between the observed molecular weight on blot (average 57.8kDa, n=18) and the 645 
calculated expected molecular weight with the method of Lambin for a gradient SDS-PAGE gel (4-646 
15%) (Figure S7)47. 647 
TMX2 variants highly dimerize and polymerize in native and ER-stress conditions 648 
We tested the effect of variants on the behavior of exogenously expressed TMX2. By in vitro 649 
mutagenesis, the single cysteine in the atypical thioredoxin domain was substituted with a glycine, 650 
p.Cys170Gly. Interestingly, ablation of the active cysteine in the TRX domain still permitted 651 
dimerization, which supports the hypothesis that this dimer is not a mixed disulfide dimer of the TRX 652 
domain with another substrate. Moreover, dimerization of TMX2 was appreciated in the TRX domain 653 
variant, even under native conditions, i.e. independently of an oxidative stress, suggesting that this 654 
domain is involved in the reversibility of the TMX2 state between monomer and dimer (Figure 7E). 655 
Furthermore, oxidative stress even induced the formation of higher molecular weight polymers in 656 
the TRX domain mutant (Figure 7C, lane 10). To determine redox state of human TMX2 pathogenic 657 
variants under different stress conditions, we overexpressed either a TMX2 variant located in the 658 
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cytosolic domain, p.Arg53Cys , or a variant in the ER lumen domain, p.Arg231Trp (Figure 7C, lanes 659 
13-18, 19-24). Strikingly, the amount of TMX2 dimer was significantly higher compared to wild-type 660 
TMX2 for both variants in both native and under all stress conditions, not only H2O2, as quantified in 661 
Figure 7 E. Dimer/ monomer ratios were increased by 10-fold (1:1), while in wild-type TMX2 this is 662 
0.1:1, showing that the pathogenic variants block the protein in a dimerized state and that affected 663 
individuals may have less monomeric protein available (Figure 7 E). Moreover, TMX2 with the 664 
natural variants also displayed higher levels of polymerization, as seen in the TRX mutant (apparent 665 
mass ~110kDa and 140kDa, observed average mass 97.1kDa and 138.9kDa with method of Lambin in 666 
n=11). Based on the linear correlation between observed and expected mass, these bands seem to 667 
represent homotrimers and tetramers of TMX2(Figure S7). Although the amount of dimer to 668 
monomer ratios under oxidative stress was also doubled or tripled in mutant p.Arg231Trp or 669 
p.Arg53Cys TMX2 compared to wild-type TMX2, the difference was no longer significant (Figure 7E, 670 
H2O2,, fourth graph). DTT treatment prevented polymerization of the variants almost completely, 671 
confirming that polymerization is (at least partially) mediated by disulfide bridge formation (Figure 672 
7E, third graph and Figure S6). Notably, in vitro mutagenized Myc-tagged TMX2 was still able to bind 673 
both CNX and SERCA2 (Figure S8).   674 
DISCUSSION 675 
We describe a disorder, characterized by developmental delay, microcephaly, impaired speech and 676 
ambulation, epilepsy and cortical malformations, with a relatively wide spectrum of severity ranging 677 
from early death to intellectual disability with mild motor impairment, resulting from recessive 678 
TMX2 variants. 679 
Redox regulatory proteins are enriched at the MAM of the smooth ER 10; 48. Some of these proteins 680 
interact with ER calcium handling proteins and regulate the calcium flux into the mitochondria, 681 
which, in turn, influences mitochondrial membrane potential and mitochondrial respiration1. 682 
Thioredoxins of the PDI family regulate the cellular redox state through oxidoreductase activity-683 
mediated disulfide bond formation and contribute to protein folding. The PDI transmembrane ER 684 
thioredoxin-related (TMX) proteins, such as MAM-associated TMX1, seem to have dual function: on 685 
the one hand in regulating protein folding, maintaining the redox environment of the ER and hereby 686 
preventing ER stress, on the other hand in regulating calcium flux in the mitochondria7. Besides 687 
regulating protein folding and calcium transport, thioredoxins in general are key molecules in the 688 
regulation of oxidative stress through scavenging reactive oxygen species (ROS), such as hydrogen 689 
peroxide49.  690 
TMX2 lacks the canonical oxidoreductase active C-X-X-C domain. However, its function as folding 691 
chaperone is suggested by our data, demonstrating (1) the dysregulation of disulfide bond and N-692 
glycosylation-related genes in TMX2-deficient fibroblasts, (2) the interaction of TMX2 with several 693 
proteins regulating protein folding and UPR and (3) the presence of both oxidized and reduced forms 694 
in the maleimide alkylation assay. In addition, our mechanistic studies discover the function of TMX2 695 
as regulator of calcium homeostasis and mitochondrial bioenergetics. TMX2 localizes at the MAM 696 
where it physically binds to calnexin and SERCA2, whereas TMX2-variant fibroblasts show decreased 697 
mitochondrial reserve capacity and lower ability to cope with oxidative stress, probably related to 698 
defective calcium flux, similarly to what was proposed for TMX1-deficient cells7. Compared to TMX1, 699 
TMX2 is highly expressed in fetal and post-natal brain. The specific TMX2 expression in the cortex 700 
during prenatal life, together with the deleterious effect of its loss of function for human cortical 701 
development, places TMX2 as a key molecule in the ER-mitochondrial redox regulation of brain 702 
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development. Although pathogenic variants in mitochondrial oxidoreductases and MAM-associated 703 
proteins have been reported as causes of pediatric neurologic disorders16-20, the TMX2 related 704 
disorder is a malformation of cortical development resulting from a defect in a member of the PDI 705 
family. 706 
TMX2 is thus an important regulator of oxidative stimuli and an intriguing aspect is its 707 
responsiveness to H2O2. The sensitivity of TMX proteins to H2O2 has received little attention, 708 
although it has been shown that their redox state dramatically changes after H2O2-treatment, as it 709 
happens for example for TMX46. The hydrogen peroxide signaling molecule has long been 710 
considered as deleterious for cellular function and as a byproduct of oxidoreductase reactions, being 711 
rapidly metabolized by catalases, glutathione-peroxidases or peroxi-redoxins49. However, more 712 
recent findings highlighted the role of H2O2 as physiological regulator of redox signaling (oxidative 713 
eustress), acting via reversible cysteine and methionine oxidation50. Additionally, H2O2 functions in 714 
higher concentrations as a mediator of pathophysiological signals (oxidative distress) leading to 715 
growth arrest and regulated cell death50. One of the main intracellular sites of H2O2 production is the 716 
ER51. Along with the activation of peroxi-redoxins as possible intermediate sensors, the role of H2O2 717 
in the development of the nervous system has been well-established51-53. Among targets of H2O2 718 
redox signaling are transcription factors of the Wnt and the Shh pathways54. Moreover, H2O2 has 719 
been recently discovered as signaling molecule controlling axonal path finding in zebra fish54 and 720 
neuronal growth cone collapse in vitro55. Hence, it is not surprising that a TMX2 variant-mediated 721 
misbalance in oxidative eustress/distress could result in impaired neuronal development.  722 
Under our experimental conditions, increased concentrations of H2O2 in the culture medium induced 723 
wild-type TMX2 dimerization. In the same maleimide alkylation assays, TMX2 redox state does not 724 
seem sensitive to ER stressors. These results reflect a physiological sensitivity of TMX2 to H2O2, 725 
possibly mimicking an adaptive response to oxidative eustress, regulating physiological steps in 726 
development52; 54.  Wild-type TMX2 dimer was still slightly present under β-mercaptoethanol 727 
reducing conditions (Fig. S6), indicating that it is partially formed through inter-disulfide bonds. The 728 
occurrence of homo-dimerization of other members of the PDI superfamily has been described 729 
earlier (for PDI56-58, PDIp59, ERp2960) and is suggested as a general mechanism to regulate PDI 730 
function13; 56. Dimers can exhibit higher chaperone or unfolding activity as described for ERp29, PDIp, 731 
CNX and CRT dimerization60.  Also, homo-dimerization of other TMX proteins has been postulated, 732 
e.g. a putative TMX1 homodimer was observed in immunoprecipitates with anti-CNX after ablation 733 
of the TRX domain active cysteines61. 734 
Our data suggest the formation of TMX2 homo-dimer/polymers, based on the evidence that 735 
observed TMX2 molecular masses on gradient gels show linearity with the predicted molecular mass 736 
by the Lambin method calculation and on the fact that the dimerization is not strictly dependent on 737 
disulfide bridge formation. Both under DTT pre-treatment in culture (of the TMX2 mutants) and by 738 
running a gel with β-mercaptoethanol, dimers are still present with an identical linear molecular 739 
mass. Since dimerization  still occurs in the TRX domain mutant independently of an active cysteine 740 
and H2O2 treatment, the dimer does not represent a heterodimer of TMX2 with a substrate formed 741 
through mixed disulfides, similar to what is described for TMX1 homo-dimerization61. Although 742 
polymers were also observed after ablation of the TRX domain cysteine, they were barely present 743 
under reducing conditions. Hence, we cannot exclude interactions of TMX2 with other substrates of 744 
identical molecular mass, through TRX domain-independent interactions. For example, N-linked 745 
glycosylation has been shown to modulate the formation of PDI polymers and in TMX2 it could 746 
mediate interaction with heterologous peptides 56.  747 
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Similar to wild-type TMX2 under oxidative stress, we observed constitutive TMX2 homodi-748 
/polymerization upon expression of the TMX2 pathogenic variants (p.Arg53Cys and p.Arg231Trp), 749 
leading to mitochondrial dysfunction, reduced maximal respiration and increased glycolysis, as seen 750 
under ER stress conditions 7; 50; 62. However, we did not detect activation of UPR in fibroblasts from 751 
affected individuals, both under native and under treatment with H2O2 (data not shown). This 752 
suggests that UPR is not the primary target of TMX2 function or that cultured fibroblasts are not the 753 
ideal test model.  754 
Another fascinating aspect is TMX2 involvement in the pathogenesis of PMG. This malformation has 755 
long been considered as a defect of postmigratory cortical organization63, with wide genetic 756 
heterogeneity, but also being a proven consequence of prenatal brain injury or disruptive events64. 757 
These aspects make genetic counseling of PMG most challenging. At brain imaging it may be difficult 758 
to distinguish PMG resulting from environmental factors (e.g. prenatal CMV infection) or from 759 
genetic defects. At MRI and pathological examination the main PMG characteristics are many small 760 
gyri with pebbled appearance, loss of normal cortical lamination, overfolding and fusion of the gyri, 761 
stippling of the white-grey matter border65, sometimes giving the appearance of generally thickened 762 
cortex. The cobblestone malformation is characterized by pebbled cerebral surface, thick cortex and 763 
striation perpendicular to the cortical surface, which reflect tracks of neuroglial cells overmigrating 764 
above the glia limitans in the subarachnoid space, overmigration sometimes being massive and 765 
leading to thinning of the cortical plate 35; 66. Cobblestone malformation is frequently associated with 766 
cerebellar and pons dysplasia and variable hydrocephalus, white matter and callosal dysgenesis. 767 
PMG and cobblestone malformation have been sporadically reported to coexist in the same genetic 768 
disorder67; 68. Pathology of the brain in two TMX2 variant affected individuals shows a complete 769 
disorganization of the cortical layers (unlayered PMG) in both and in one of them (P10) diffusely 770 
overmigrating neurons, typical of cobblestone malformation, together with scattered white matter 771 
calcifications and pseudocysts, suggestive of a disruptive (CMV-like) event. Unlayered PMG is 772 
supposed to be caused by an early disruption of cortical development between 16-24 weeks 773 
gestation69 and can also be observed in metabolic causes of PMG such as Zellweger disease (a 774 
peroxisomal biogenesis disorder, characterized by mislocalization of catalase), or lining non-genetic 775 
schizencephalic clefts64; 70. A mixture of disruptive and developmental migratory abnormalities has 776 
been reported for the brain disorder caused by the Zika virus (ZIKV) infection, where the effect on 777 
neuronal proliferation and migration is more prominent than in other more common congenital 778 
infections, i.e. CMV 71. We demonstrate that TMX2-related PMG is a disorder of neuronal migration 779 
and cortical organization, without evidence of vascular or inflammatory disruption, in some cases 780 
with radiological aspect resembling an infectious i.e. non-genetic cause, in other cases 781 
microscopically showing the cobblestone malformation. These observations support the view that 782 
PMG and cobblestone are cortical malformations that can share a common pathogenesis and 783 
represent different severity of the spectrum72; 73. 784 
It is possible that some of the TMX2 related malformations are caused by lack of physiological 785 
response to regulators of neuronal development (hypothetically H2O2-mediated axonal pathfinding) 786 
and some are the effect of abnormal oxidoreductase-mediated protein folding and calcium 787 
homeostasis, with a secondary mitochondrial dysfunction. Although no UPR stimulation was found 788 
in TMX2 deficient cells, TMX2 also plays a role in regulation of UPR and apoptosis, both mechanisms 789 
essential for regulation of neuronal proliferation and cortical organization74.  790 
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Our observation shows how in humans a genetic disorder of cellular redox adaptation mechanisms 791 
can be the cause of neuronal proliferation and migration disorders, with characteristics of a 792 
disruptive event. These studies also provide a mechanistic explanation for the fact that human brain 793 
development is driven by steps strictly regulated in time and space, including individual response to 794 
environmental stimuli, e.g. to redox signaling molecules and changes in cellular redox state.  Protein 795 
disulfide isomerase family members might prove to be major players in this process. 796 
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 1077 
FIGURE TITLES AND LEGENDS 1078 
Figure 1. Features and brain MRI of individuals with TMX2 variants. P indicates the code of the 1079 
probands as used in Table 1 and S4. P1 (A-E): affected member of family 1. A: The photograph shows 1080 
mild microcephaly and no overt dysmorphic features. The MRI scan at birth shows T2 weighted 1081 
images, of (B) parasagittal plane, (C) axial at the level of basal ganglia, (D) axial at the level of parietal 1082 
areas and € axial at the level of pons and cerebellum. Both the parasagittal and the two axial 1083 
cerebral sections show diffuse polymicrogyria of the cortex, normal myelination, hypointensity of 1084 
the thalami (left axial) and normal cerebellum. P2 (F-H): MRI of the affected individual from family 2 1085 
at 19 months of age. (F) axial FLAIR -, (G) coronal T2 -, (H) coronal inversion recovery- weighted 1086 
images all showing bilateral diffuse thickened cortex extending through frontal, parietal and occipital 1087 
areas, resembling polymicrogyria, with sparing of the cerebellum. The lateral ventricles are enlarged 1088 
and asymmetric; the periventricular white matter volume is strongly reduced. P3 (I): axial T2 1089 
weighted image of the affected child of family 3 at birth, showing diffuse bilateral polymicrogyria of 1090 
the cortex, mild dilatation of the posterior horns of the lateral ventricles and delayed myelination. 1091 
P4 (J-L) and P5 (M-O): affected siblings of family 4, at the age of 12 (P4) and 23 years (P5), 1092 
respectively (J and M) sagittal T1-, (K and N) axial T2- weighted images at the level of basal ganglia 1093 
and (L and O) the cerebellum, showing thin corpus callosum, loss of periventricular white matter and 1094 
volume of thalami, deep cerebral sulci and mild cerebellar atrophy. No cortical malformation is 1095 
present. P6 (P-S) is the index of family 5. (P) Axial T2 and (Q) parasagittal T1 images showing 1096 
abnormally thick cortex, atrophic thalami, in (Q) the frontal cortex looks pachygyric. (R) Axial T2 1097 
FLAIR and (S) axial T1 weighted images showing diffusely thickened cortex, most prominent in 1098 
parietal areas and moderately enlarged lateral ventricles. P9 (T-V): affected proband of family 6, at 1099 
the age of 11 months. Axial T2 weighted images (T-U) showing brain atrophic changes with bilateral 1100 
pallidus (red arrow) and posterior limb of the internal capsule (red arrowhead) T2 high signal 1101 
intensity, as well as significant delayed myelination. Globi pallidi are severely atrophic. (V): Both 1102 
globi pallidi, posterior limb of the internal capsules, optic radiations (black arrowhead) and 1103 
brainstem tract (not shown) abnormalities are also noted on DWI and confirmed by ADC map (not 1104 
shown) indicating restricted diffusion. P10 (W-Y): MRI at birth of the proband from family 7. (W) 1105 
midsagittal, (X-Y) axial T2 weighted images. (W) mild hypoplasia of the pons, thin corpus callosum. 1106 
(X) hypoplastic cerebral peduncles, bilateral abnormal cortex with polymicrogyric appearance. (Y) 1107 
diffuse bilateral polymicrogyria, enlarged lateral ventricles with pseudocyst in the left occipital horn 1108 
(black arrowhead), and white matter loss, the combination including the pseudocyst being typically 1109 
seen in CMV infections. 1110 
Figure 2. Brain pathology of individuals with TMX2 variants. A-C, E-G: affected individuals; D and H: 1111 
age matched controls.  Upper panel: macroscopic brain appearance of P1 (A-B) and P10 (C). Sagittal 1112 
view (A) and coronal section (B) show diffuse bilateral excessive amount of small gyri 1113 
(polymicrogyria) of the cerebral cortex (most affected areas indicated by white arrows), compared to 1114 
control brain (D).  (C) coronal section through the posterior parts of the brain shows asymmetric 1115 
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hemispheres and bilateral polymicrogyria, especially in the occipital lobes (white arrow). The image 1116 
of the normal neonatal age-matched brain (40GW), shows normal size and number of the gyri and 1117 
sulci (lateral view of the right hemisphere) (D). Lower panel: Histological sections of individuals P1 1118 
(E-F), P10 (G) and age matched control brain cortex (H) show absence of normal cortical layers in 1119 
affected individuals, with bands of neurons laying perpendicular to the cortical surface in E, F and G. 1120 
Undulating bands of neurons (arrow heads), entrapped pial vessels mimicking fusion of the cortical 1121 
layer (arrow), and thickened leptomeninges are compatible with (unlayered) polymicrogyria (E: H&E, 1122 
10x, F: H&E, 5x, G: Lugol-PAS stain, 3x). Control histological section of the frontal dorsolateral 1123 
telencephalic gyrus of the neonatal age-matched brain (H: H&E 5x), showed the regular organization 1124 
of the six-layered neonatal neocortex, parallel to the pia surface. 1125 
 1126 
Figure 3. Genomic and transcriptomic analysis of TMX2 variants. A. Schematic overview of TMX2, 1127 
protein domains and the discovered variants in affected individuals (GSDS 2.0) B. Levels of expressed 1128 
TMX2 messenger RNA in individuals P1, P2 and P3. Ct values were normalized with two 1129 
housekeeping genes CLK2 and RNF111;∆∆ CT ƌelatiǀe to ĐoŶtƌol ;Ŷ=ϮͿ. Data are represented as the 1130 
mean ± SEM. Statistical two-tailed unpaired t-tests were performed with confidence interval 95%. C. 1131 
Allele specific qPCR of individual P1. Ct values were normalized with two housekeeping genes CLK2 1132 
aŶd ‘NFϭϭϭ ;∆∆ CT ƌelatiǀe to control (n=4).  D. Aberrant splicing of the P2 and control TMX2 alleles. 1133 
Graphic illustration (adapted from IGV Sashimi plot) of the percentage of TMX2 transcripts in 1134 
RNAseq data of total RNA of individual P2 and 1 control individual. Percentages are calculated for 1135 
each transcript compared to the total TMX2 (wild-type and alternative) transcript reads (GRCh38), 1136 
and E. Aberrant splicing of the P2 and control TMX2 alleles. Aligned uniquely mapped reads in the 1137 
exon 5-7 region of TMX2 were quantified (reads per million) using IGV 2.3.26. Three distinct 1138 
alternative species of TMX2 transcript were identified, consistent with intron 6 retention, exon 6 1139 
skipping and exon 6 internal splice site usages, the latter two only from the P2 allele. Total uniquely 1140 
mapped reads for control and individual P2 were 64 745 034 and 54 200 090 respectively. 1141 
 1142 
Figure 4. Gene ontology (GO) analysis of differentially expressed genes in TMX2 variants. A. DAVID 1143 
Functional Annotation Clustering (FAC) analysis of the top 1000 differentially expressed genes (DEGs) 1144 
obtained by comparison of two TMX2 affected individuals vs. three age and gender matched control 1145 
RNA samples (p-value <0.05). B. upper panel: LogFC of all differentially expressed disulfide bond 1146 
associated genes in TMX2 affected individuals with an FDR<0.05, lower panel: -Log(FDR) of these 1147 
genes (-log(FDR)<1.3). C. Ingenuity Pathway analysis (IPA) was performed to determine activated 1148 
and inhibited biological functions downstream of the differentially expressed genes in TMX2 affected 1149 
individuals. Stringency was determined with 90% confidence interval by only considering activation 1150 
Z-scores higher than 1.65 (activation) or lower than -1.65 (inhibition). Individual p-values of each 1151 
function are mentioned within the bars and were always lower than 10-6. Abbreviations: GO, Gene 1152 
ontology; UP, UniProtKB; FDR, False discovery rate; FC, Fold Change; KEGG, Kyoto Encyclopedia of 1153 
Genes and Genomes. 1154 
Figure 5. Proteomics analysis of exogenous TMX2 interacting proteins. A. HEK293T cells were 1155 
transfected with Myc-tagged TMX2 or negative control β-lactamase for 24 hours, followed by IP with 1156 
αMyc antibody and LC-MS/MS on bead pellets. Detected proteins interacting with TMX2-Myc but 1157 
not with Lac-Myc were filtered based on average Mascot score in n=4 experiments (significant if 1158 
higher than 40). Cytoscape String App visualized all 71 proteins reproducibly and selectively 1159 
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interacting with TMX2 according to pathway involvement (dark blue=Protein folding, light blue= 1160 
Calcium Homeostasis, Red= ER associated degradation (ERAD) and Unfolded Protein Response 1161 
(UPR), Green= Mitochondrial signaling, Pink= Mitosis, Orange= Translation, Yellow= Nucleus 1162 
Transport, Black=Golgi transport, Grey=unassigned). Known PDI interactors Calnexin and SERCA2 1163 
were found in the top 10 highest interactions, and are circled in red.  B. HEK293T cells were 1164 
transfected with Myc-tagged TMX2 or negative control β-lactamase for 24 hours, followed by 1165 
reciprocal immunoprecipitation of SERCA2 (Mouse monoclonal anti-SERCA2 ATPase ab2861) and 1166 
Calnexin (Monoclonal Rabbit anti-human CNX C5C9), SDS PAGE and detection of TMX2 with αMyc 1167 
antibody. IP input is shown after reducing western blot. 1168 
 1169 
 1170 
Figure 6. Bioenergetics profiles of skin fibroblasts from affected individuals with TMX2 variants. A, 1171 
B. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) bioenergetics profiles 1172 
of fibroblasts derived from healthy controls (n=4) and affected individuals (P1, P2, P3). Fibroblasts 1173 
were challenged with sequential administration of oligomycin to inhibit ATP synthase, FCCP to elicit 1174 
maximal respiration, rotenone to inhibit complex I, and antimycin to inhibit complex III and fully 1175 
block respiration. The parameters analyzed in the profiles were: basal respiration, respiration 1176 
dedicated to ATP production, (measured as difference between basal respiration and the respiration 1177 
after oligomycin injection), mitochondrial reserve capacity (as difference between maximum reserve 1178 
capacity and basal respiration), and rotenone sensitive respiration (which accounts for the 1179 
respiration dependent on complex I), basal glycolysis and oligomycin stimulated glycolysis. C, D. 1180 
Fibroblasts derived from affected individuals show significant reduction in mitochondrial reserve 1181 
capacity and in the complex I activity (C) while showing a significant potentiation of glycolysis in 1182 
basal condition and upon stimulation with oligomycin (D). E. The analysis of mitochondrial 1183 
respiration in galactose medium (where glycolysis is not permitted) highlights the inability of the 1184 
TMX2 variant fibroblasts to potentiate basal mitochondrial respiration and mitochondrial complex I 1185 
activity. (*p < 0.05; **p < 0.01; ****p < 0.0001; one-way ANOVA (C, D) and two-way ANOVA (E) 1186 
followed by Dunnett's multiple-comparison post doc test). Graphs represent mean ± SEM. 1187 
Figure 7. Redox state assays of wild-type and variant TMX2. A-B. Non-reducing western blot of 1188 
exogenous wild-type TMX2 versus endogenous control PDI (PDIA1) in HEK293T cells, showing that 1189 
TMX2 occurs in an oxidized and reduced monomeric form, while during H2O2 treatment a dimer is 1190 
formed (OX dimer). A) left panel shows the blot after incubation with anti-wild-type TMX2 1191 
antibodies; middle panel: incubation with anti-Myc antibodies; right panel: anti-PDI control protein 1192 
antibodies. B) Control experiment after expression of exogenous control β-lactamase (Lac-Myc); 1193 
immunoblotting performed with the same antibodies as in A.  Native: untreated cells; BFA: cells 1194 
treated with ER stress inducer Brefeldin A; DTT: cells treated with reducing agent DL-Dithiothreitol; 1195 
H2O2: cells treated with hydrogen peroxide.  1196 
C. Non-reducing western blot with similar experimental setup as in A and B. but here also after 1197 
addition of ER stress inducers Tunicamycin ( TM) and Thapsigargin (TG). Redox states of TRX domain 1198 
p.Cys170Gly variant (lanes 7-12) and affected individual p.Arg53Cys variant (lanes 13-18) and 1199 
p.Arg231Trp variant (lanes 19-24) were determined simultaneously. Detection was performed with 1200 
anti-Myc antibody. D-E. Semi quantitative densitometry calculations of TMX2 dimer/monomer ratios 1201 
in native, ER stress, oxidative and reductive environment for wild-type TMX2, n=4 western blots 1202 
from biological replicates (D.) and comparing wild-type TMX2 to p.Cys170Gly, p.Arg53Cys and 1203 
p.Arg231Trp variants. Data are represented as the mean ± SEM. Statistical two-tailed unpaired t-1204 
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tests were performed with confidence interval 95% in Graphpad Prism 8 ;*p < Ϭ.Ϭϱ; **p < Ϭ.01; 1205 
***p<Ϭ.ϬϬϭ, ****p < Ϭ.ϬϬϬϭͿ.1206 
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TABLE TITLES AND LEGENDS 
Table 1 Summary of TMX2 variants and phenotypes. 
 Affected 
individuals 
Family 1- P1 Family 2- P2 Family 3-P3 Family 4- P4  Family 4- P5  Family 5-P6  24 Family 5-P7  24 Family 6- P8  Family 6- P9  Family 7- P10 Family 8- P11  Family 8- P12  Family 9- P13 Family 10- P14 
Ancestry Dutch Portuguese White British Puerto Rican Puerto Rican Spanish Spanish Arab Arab Dutch Iraqi Iraqi Pakistani Mexican 
cDNA 
alteration 
c.164A>C; 
c.391dup 
c.614G>A 
Homozygote 
c.157C>T;     
c.757C>T 
c.166G>C 
Homozygote 
c.166G>C  
Homozygote 
c.326A>G;    
c.691C>T 
c.326A>G; 
c.691C>T 
Not tested 
 c.532G>A 
Homozygote 
c.164A>C;c.609
_614+15del 
c.184G>C 
Homozygote 
c.184G>C 
Homozygote 
c.178G>A 
Homozygote 
c.349A>G;    
c.691C>T 
Protein 
alteration 
p.Asp55Ala;p.L
eu131Profs*6 
p.Arg205Gln 
p.Arg53Cys;p.A
rg253* 
p.Gly56Arg p.Gly56Arg 
p.Asp109Gly;p.
Arg231Trp 
p.Asp109Gly;p.
Arg231Trp 
Not tested p.Ala178Thr 
p.Asp55Ala;p.S
er203_Thr204d
el 
p.Asp62His  p.Asp62His  p.Asp60Asn 
p.Ile117Val;p.A
rg231Trp 
Gender Male Male Female Male Female Female Male Female Female Male Male Male Female Female 
Head size 
(OFC)  
Primary 
microcephaly  
( - 3 SD at 
birth) 
Microcephaly  
(n.a. at birth;           
- 4.5 SD 
current)          
Primary 
microcephaly         
(- 2.5 SD at 
birth,                   
- 6.7 SD 
current) 
Borderline 
microcephaly 
(n.a. at birth;           
- 2 SD current) 
Microcephaly 
(n.a. at birth;           
- 3 SD current) 
Microcephaly           
(- 2 SD at birth;          
- 4 SD current) 
Microcephaly      
(n.a. at birth;           
- 3 SD current) 
Undefined   (0 
SD at birth, 
later n.a. )    
Microcephaly    
(0 SD at birth;          
- 5.5 SD 
current) 
Primary 
microcephaly          
(- 2.5 SD at 
birth) 
Microcephaly         
(n.a. at birth;           
- 4.5 SD 
current) 
Primary 
microcephaly          
(- 2,5 SD at 
birth;                 
- 3.5 SD 
current) 
Normal                
(n.a. at birth;           
- 0.5 SD 
current) 
Normal                
(n.a. at birth;           
- 0.8 SD 
current) 
Neurological 
impairment 
No 
developmental 
milestonesa 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
CP, no speech 
or ambulation 
No 
developmental 
milestonesa 
No 
ambulation, 
few words  
 No speech or 
ambulation 
Able to walk 
with support, 
few words 
IQ 62; 
language 
disorder; 
hyperactive 
behavior, able 
to walk 
Survival/ age 
at last 
examination 
Deceased at 
week 2 
7 yr. 9 yr. 28 yr. 25 yr. 13 yr. 11 yr. 
Deceased at 6 
yr. 
1.5 yr. 
Deceased at 1 
week 
10 yr. 5 yr. 4.8 yr. 11.5 yr. 
Epilepsy 
Generalized, 
apnea, status 
epilepticus 
Generalized, 
absence, 
spasms 
Generalized 
seizures 
Focal seizures 
Myoclonic-
absence, GTC 
No seizures GTC GTC Focal seizures 
Apnea, 
diaphragmatic 
myoclonia 
Generalized 
tonic, 
myoclonic 
seizures 
GTC  
Myoclonic 
status 
epilepticus 
No seizures 
MRI Polymicrogyria Polymicrogyria Polymicrogyria 
Progressive 
brain atrophy 
Progressive 
brain atrophy 
Pachygyria Pachygyria 
Severe brain 
atrophy 
Sever brain 
atrophy 
Polymicrogyria n.a. Polymicrogyria 
Hemihypertrop
hy and frontal 
dysgyria 
Normal 
Brain autopsy 
Unlayered 
polymicrogyria 
and complete 
cortical 
disorganization 
n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Diffuse 
polymicrogyria 
and 
cobblestone-
like 
malformation 
n.a. n.a. n.a. n.a. 
a These individuals passed away soon after birth. Microcephaly is defined as an OFC <-2.5SD. Abbreviations: CP, signs of cerebral palsy; n.a., not assessed or not available; OFC, 
Occipitofrontal circumference; yr., year; SD, standard deviations; GTC, Generalized tonic clonic seizures 
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